identified EPHA2 as a tumor antigen for medulloblastoma and designed trivalent CAR-T cells (EPHA2, HER2, IL13Rα2) to perform preclinical studies and validated that intrathecal delivery of the trivalent CAR-T could be an effective treatment for metastatic medulloblastoma (56). The gene discussed is EPHA2; the disease is medulloblastoma.